Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Liberty Latin America Insider Angoitia Alfonso De Buys $5.06M of Stock
Angoitia Alfonso De bought 249,214 shares of Liberty Latin America Ltd. at $20.22 to $20.30 a share (average $20.30) in 2 transactions, worth $5.06M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 725,565 (+51.1%).
United States Antimony Corp reported Q3 2026 revenue of $10.1 million, a 16% increase year-over-year, driven by a 68% surge in antimony pounds sold. Despite a 113% increase in gross profit to $4.3 million, the company reported a net loss of $9.5 million, impacted by non-cash stock-based compensation and an unrealized loss on its Larvotto Resources investment.
The Invesco Galaxy Ethereum ETF entered into a digital assets custody agreement with BNY Mellon to establish segregated accounts for the safekeeping of the Trust's ether holdings. The agreement has an initial five-year term and complements the Trust's existing custody arrangement with Coinbase. This move diversifies the Trust's custodial infrastructure for its underlying digital assets.
Lineage Cell Therapeutics Signs $2.4M M&A Deal with NeuroAirmid Therapeutics, Inc.
Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics, Inc., adding a clinical-stage neural cell therapy program (HUNT1) for Huntington’s Disease to its pipeline. The deal involved a $2.4 million upfront cash payment and the assumption of a co-funding obligation for an ongoing Phase 1b/2a clinical study supported by CIRM.
Value
$2.4M
Counterparty
NeuroAirmid Therapeutics, Inc.
“Today, we closed the acquisition of NeuroAirmid Therapeutics adding HUNT1, a third clinical-stage asset to our development pipeline. HUNT1 is a pluripotent stem cell derived, clinical-stage neural cell therapy program, with the potential to validate a new cell-based treatment modality for Huntington’s Disease.”
Brian M. Culley, Lineage CEO
“This transaction reflects the disciplined approach to capital allocation and strategic fit that we believe our investors have come to expect from Lineage. HUNT1 was created on the same proprietary cell line that Lineage uses and is compatible with its AlloSCOPE “5D” technology, providing us with a head start on our planned contributions.”
Equillium reported third quarter 2026 financial results, highlighting the initiation of a Phase 1 clinical trial for EQ504 with proof-of-mechanism data expected in Q2 2027. The company strengthened its balance sheet with a $20 million financing tranche closed in October 2026, extending its cash runway into 2029.
“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program. We believe EQ504’s differentiated immunoregulatory mechanism of action, without broad immune suppression, has the potential to address key epithelial and immune pathways involved in inflammatory disease.”
Bruce Steel, Chief Executive Officer of Equillium
“We look forward to reporting proof-of-mechanism data in the second quarter of 2027, which we expect will inform our planned proof-of-concept study in ulcerative colitis that we expect to initiate in the second half of 2027. Supported by our strong financial position, we remain focused on advancing EQ504 to patients while continuing to evaluate its broader therapeutic potential.”
Snail, Inc. reported operational highlights for the third quarter of 2026, including 1.2 million units sold of ARK: Survival Ascended and 559,000 units of ARK: Survival Evolved. The company also highlighted the launch of several new titles including Honeycomb: The World Beyond and Stoneguard, alongside the debut of its AI gaming companion initiative, Non-Human Player (NHP).
Sanara MedTech reported Q3 2026 net revenue of $28.4 million, an 8% increase year-over-year, and Adjusted EBITDA of $5.6 million. The company recorded a net loss from continuing operations of $1.3 million, which included $3.0 million in legal and advisory costs related to its pending merger with MiMedx Group, Inc.
Ricardo Sotelo resigned as Chief Financial Officer of Exyn Technologies on November 9, 2026. Benjamin Williams, the company's Interim CEO, has been designated as the principal financial and accounting officer effective immediately, with no additional compensation for the role.
Varagon Capital Debt Financing Update with Sumitomo Mitsui Banking Corporation
Varagon Capital Corporation entered into an amendment to its senior secured revolving credit facility (SMBC Facility) to extend its maturity and availability periods. For extending lenders, the revolver availability period was extended to November 2030 and the final maturity date to November 2031, while the applicable margin for benchmark loans was increased to 2.25% per annum.
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on integrin-based therapeutics, with its lead candidate PLN-101095 currently in Phase 1a/1b trials. The company reports significant net losses since inception and expects to require substantial additional capital to fund its ongoing research and development activities.
Rhinebeck Bancorp, Inc. reported net income of $3.15 million for the quarter ended September 30, 2026, compared to $2.70 million in the prior year period. The company completed its conversion to a fully public company on July 21, 2026, resulting in a significant increase in total stockholders' equity to $220.8 million.
Socket Mobile reported a 9% increase in Q3 2026 revenue to $3.39 million, though year-to-date revenue remains down 8.9% compared to 2025. The company continues to operate at a loss, reporting a net loss of $0.79 million for the quarter and $3.04 million for the first nine months of 2026, as it manages high operating expenses relative to gross profit.
Eledon Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $69.7 million and progress in its tegoprubart clinical program. The company remains on track to initiate its global Phase 3 LEGACY trial in kidney transplantation in Q4 2026 and recently received FDA Fast Track designation for the candidate.
Term
Q3 2026
“We continue to execute across our key strategic priorities and make meaningful progress in the tegoprubart clinical program across multiple transplant types, including plans to initiate our global Phase 3 LEGACY trial in kidney transplantation by year end.”
David-Alexandre C. Gros, M.D., Chief Executive Officer
Teva Pharmaceutical Industries CAO Amir Weiss Sells $744K of Stock
Amir Weiss, CAO, sold 17,289 shares of Teva Pharmaceutical Industries Ltd at $43.03 to $43.15 a share (average $43.04) in 3 transactions, worth $744K in total on Nov 9, 2026. Shares held after the trade: 3,537 (-72.9%).
Elevra Lithium President Canada & Group COO Sylvain Collard Buys $74.8K of Stock
Sylvain Collard, President Canada & Group COO, bought 30,000 shares of Elevra Lithium Ltd at $2.49 a share, worth $74.8K in total on Nov 10, 2026. Shares held after the trade: 30,000.
The Marzetti Company's Board of Directors declared a quarterly cash dividend of $1.05 per common share, marking 64 consecutive years of dividend increases. The dividend is payable on December 31, 2026, to shareholders of record as of December 4, 2026. The company also reported the results of its 2026 Annual Meeting, where shareholders elected three directors and approved executive compensation.
American Homes 4 Rent Insider Jack E. Corrigan Buys $101K of Stock
Jack E. Corrigan bought 4,800 shares of American Homes 4 Rent at $20.88 to $21.26 a share (average $21.08) in 4 transactions, worth $101K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 25,000 (+4.2%).
US Foods Holding Corp. has increased its board size to nine and appointed Lisa M. Lambert as an independent director, effective November 12, 2026. Ms. Lambert, a venture capital executive and former Chief Technology and Innovation Officer at National Grid, is expected to enhance the board's oversight of technology strategy, AI initiatives, and cybersecurity.
For the 13 weeks ended October 3, 2026, Fossil Group reported net sales of $271.2 million and net income attributable to the company of $11.7 million, a significant recovery from the $39.9 million loss in the prior year period. For the 39-week period, the company achieved a narrow net income of $0.2 million compared to a $59.7 million loss in 2025, driven by improved gross margins and reduced operating expenses.
Shimmick Corporation reported a net income of $0.8 million for the third quarter of 2026, a significant improvement from a $4.4 million loss in the prior year period, despite a slight decrease in revenue to $135.8 million. For the nine months ended October 2, 2026, the company reduced its net loss to $8.4 million compared to $22.5 million in 2025, driven by improved gross margins and equity in earnings from joint ventures.
Arcadia Biosciences reported third-quarter 2026 financial results, highlighted by a 24% year-over-year increase in total revenues to $1.6 million. The growth was primarily driven by record quarterly sales for the Zola coconut water brand, which benefited from strong summer promotional programs and expanded distribution.
Term
Q3 2026
“The third quarter was very strong for Zola® with revenues growing 24% compared to the same quarter last year, resulting in the highest quarterly sales the brand has ever reported.”
T.J. Schaefer, CEO of Arcadia
“We are extremely excited to begin shipping our newly formulated espresso flavor this month after receiving pre-launch commitments from several of our leading customers.”
Binah Capital Group reported a significant increase in net income to $4.89 million for the nine months ended September 30, 2026, compared to $2.14 million in the prior year period. Total revenues grew to $145.8 million, driven primarily by higher commission and advisory fee income, while the company maintained a strong cash position of $13.2 million.
Zevia PBC President & CEO Alexandre Ruberti Buys $99.9K of Stock
Alexandre Ruberti, President & CEO, bought 81,300 shares of Zevia PBC at $1.23 a share, worth $99.9K in total on Nov 9, 2026. Shares held after the trade: 1,295,710 (+6.7%).
Middleby Corp reported net sales of $1.90 billion for the first nine months of 2026, up from $1.75 billion in the prior year, though net earnings were significantly impacted by a $129.1 million loss from discontinued operations. The company completed the Midera spin-off during the period, resulting in a $780.2 million reduction in stockholders' equity.
Sunshine Silver Mining & Refining Company completed its IPO in June 2026, raising $291.9 million in net proceeds, significantly strengthening its cash position to $261.4 million. The company reported a net loss of $50.9 million for the nine months ended September 30, 2026, driven primarily by increased pre-development and general administrative expenses as it scales operations.
TriplePoint Private Venture Credit Inc. reported a significant turnaround for the nine months ended September 30, 2026, with a net increase in net assets resulting from operations of $39.5 million compared to a $3.0 million loss in the prior year period. This improvement was primarily driven by $34.2 million in net change in unrealized gains on investments, despite a slight decrease in total investment income.
Northpointe Bancshares Inc. is an emerging growth company that operates as a non-accelerated filer. The filing highlights risks related to the mortgage banking sector, including the proposed sale of its distributed retail and consumer direct mortgage origination channels and the impact of prolonged elevated interest rates on loan demand and liquidity.
Steris $1.5B Debt Financing with J.P. Morgan Securities LLC
STERIS plc's subsidiary, STERIS Irish FinCo Unlimited Company, priced an offering of $1.5 billion in senior notes, consisting of $750 million due 2033 at 5.650% and $750 million due 2036 at 5.875%. The proceeds will be used to fund the pending acquisition of Xodus Medical, Inc., transaction expenses, and general corporate purposes.
Virgin Galactic reported a net loss of $58.8 million for the third quarter of 2026, an improvement from the $64.4 million loss in the prior year period. The company is focused on developing its next-generation Delta Class vehicles while managing a significant reduction in research and development expenses as it transitions through its flight fleet development phases.
Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at a public offering price of $1.60 per share. The company also granted underwriters a 30-day option to purchase an additional 2,812,500 shares, bringing the total potential gross proceeds to approximately $34.5 million. Net proceeds will be used to repay a portion of outstanding term loans under its Perceptive Credit Facility and for general corporate purposes.